SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (39412)11/27/2012 7:18:19 PM
From: Ian@SI  Respond to of 52153
 
Thanks. I guess I'll have to go with Needham's upgrade and estimate ($9), or Ladenberg Thalmann's target of $8, then see what happens if and when FDA approval happens. (I may have mixed and matched names and prices.)



To: Biomaven who wrote (39412)11/27/2012 9:08:00 PM
From: mcbio  Read Replies (1) | Respond to of 52153
 
Don't the apparently clear positive results today in PDP at least increase the odds of success in AD and schizophrenia?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News